These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 30969023)
21. PD-1 blockade combined with decitabine to treat refractory peripheral T-cell lymphoma not otherwise specified: A case report and review of literature. Han X; Liu X; Zhang C; Wen Q; Zhang X J Cancer Res Ther; 2023 Dec; 19(6):1680-1684. PubMed ID: 38156938 [TBL] [Abstract][Full Text] [Related]
22. Low-dose chidamide restores immune tolerance in ITP in mice and humans. Zhao HY; Ma YH; Li DQ; Sun T; Li LZ; Li P; Liu XG; Zhou H; Hou Y; Liu Y; Han PP; Zhao YJ; Jing FM; Peng J; Hou M Blood; 2019 Feb; 133(7):730-742. PubMed ID: 30552097 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review. Jin J; Zheng C; Wu S Medicine (Baltimore); 2018 Jan; 97(2):e9611. PubMed ID: 29480865 [TBL] [Abstract][Full Text] [Related]
24. Chidamide Maintenance Therapy Following Induction Therapy in Patients With Peripheral T-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Case Series From China. Guo W; Wang X; Li J; Yin X; Zhao Y; Tang Y; Wang A; Bai O Front Oncol; 2022; 12():875469. PubMed ID: 35747802 [TBL] [Abstract][Full Text] [Related]
25. Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma. Wen T; Sun G; Jiang W; He X; Shi Y; Ma F; Liu P EBioMedicine; 2023 Jan; 87():104420. PubMed ID: 36592514 [TBL] [Abstract][Full Text] [Related]
26. Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells. Wu YF; Ou CC; Chien PJ; Chang HY; Ko JL; Wang BY Phytomedicine; 2019 Mar; 56():94-102. PubMed ID: 30668358 [TBL] [Abstract][Full Text] [Related]
27. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells. Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980 [TBL] [Abstract][Full Text] [Related]
28. A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes. Liu Z; Ding K; Li L; Liu H; Wang Y; Liu C; Fu R Biomed Pharmacother; 2016 Oct; 83():1032-1037. PubMed ID: 27541047 [TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus-positive nodal peripheral T cell lymphomas: clinicopathologic and gene expression profiling study. Ha SY; Sung J; Ju H; Karube K; Kim SJ; Kim WS; Seto M; Ko YH Pathol Res Pract; 2013 Jul; 209(7):448-54. PubMed ID: 23735590 [TBL] [Abstract][Full Text] [Related]
30. Determination of chidamide in rat plasma and cerebrospinal fluid. Yang H; Li C; Chen Z; Mou H; Gu L Regul Toxicol Pharmacol; 2018 Oct; 98():24-30. PubMed ID: 30008379 [TBL] [Abstract][Full Text] [Related]
31. Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma. Song W; Chen Z; Shi C; Gao Y; Feng X; Li H; Li Z; Zhang M Hematol Oncol; 2023 Apr; 41(2):257-266. PubMed ID: 34854108 [TBL] [Abstract][Full Text] [Related]
33. Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL. Liao Z; Lv X; Liu S; He Z; Chen S; Wang L; Li W; Li Y Asia Pac J Clin Oncol; 2018 Oct; 14(5):e252-e258. PubMed ID: 29368793 [TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway. Zhou J; Zhang C; Sui X; Cao S; Tang F; Sun S; Wang S; Chen B Invest New Drugs; 2018 Aug; 36(4):571-580. PubMed ID: 29504068 [TBL] [Abstract][Full Text] [Related]
35. Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide. Chen J; Zuo Z; Gao Y; Yao X; Guan P; Wang Y; Li Z; Liu Z; Hong JH; Deng P; Chan JY; Cheah DMZ; Lim J; Chai KXY; Chia BKH; Pang JWL; Koh J; Huang D; He H; Sun Y; Liu L; Liu S; Huang Y; Wang X; You H; Saraf SA; Grigoropoulos NF; Li X; Bei J; Kang T; Lim ST; Teh BT; Huang H; Ong CK; Tan J Clin Epigenetics; 2023 Feb; 15(1):19. PubMed ID: 36740715 [TBL] [Abstract][Full Text] [Related]
36. Expression of Programmed Cell Death-1 and Programmed Cell Death Ligands in Nodal Peripheral T-Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance. Asawapanumas T; Tangnantachai N; Sukswai N; Assanasen T; Chanswangphuwana C; Lawsut P; Polprasert C; Rojnuckarin P; Bunworasate U; Wudhikarn K Acta Haematol; 2022; 145(5):542-552. PubMed ID: 35235931 [TBL] [Abstract][Full Text] [Related]
37. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy. Gao S; Li X; Zang J; Xu W; Zhang Y Anticancer Agents Med Chem; 2017; 17(6):802-812. PubMed ID: 27592546 [TBL] [Abstract][Full Text] [Related]
38. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer. Zhao B; He T Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499 [TBL] [Abstract][Full Text] [Related]
39. Chidamide alleviates TGF-β-induced epithelial-mesenchymal transition in lung cancer cell lines. Lin SH; Wang BY; Lin CH; Chien PJ; Wu YF; Ko JL; Chen JJ Mol Biol Rep; 2016 Jul; 43(7):687-95. PubMed ID: 27188428 [TBL] [Abstract][Full Text] [Related]
40. Pyroptotic macrophages promote proliferation and chemotherapy resistance of peripheral T-cell lymphoma via TLR4 signaling pathway. Zhang H; Li L; Zhang Z; Gao S; Yang M; Ma W; Li H; Zhao W; Yang H; Zhang Y; Zhao S Cancer Sci; 2024 Jul; 115(7):2444-2460. PubMed ID: 38613253 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]